Building a Research Purchase Brief for Internal Approval

An internal purchase brief should explain why a proposed item is relevant and what remains to be checked. A product name and a requested budget rarely tell an approver enough. The most useful brief connects the research need to the candidate, the evidence available and the decision being requested.

The phrase “buy MOTS-C UK” can describe commercial intent, but an organisation still needs an accountable purchasing process. This article concerns the internal approval brief, rather than the initial message to a seller. It does not establish permission for clinical use or certify a commercial product.

Start with the decision the approver must make

The opening paragraph should state whether approval is sought to obtain further information, reserve funds or proceed with an assessed purchase. Those requests involve different commitments. Ambiguous wording can make an exploratory enquiry appear to be a completed technical recommendation.

The brief should also identify the responsible project and the person who assessed relevance. Where the technical review has not happened, that limitation should be visible. A purchasing form should not imply scientific agreement merely because mandatory fields have been completed.

Show how the candidate relates to the project

The researcher should explain the relevant characteristics in language the approver can follow. A long scientific background is unnecessary if it does not affect the choice. The brief needs enough context to show why the candidate is being considered and which alternatives remain open.

The EvoraCare catalogue entry for KLIKMOTS-C can identify the item under discussion. Its inclusion in a brief should be described as a product reference, rather than evidence that the organisation has approved the listing.

Retain uncertainties beside the recommendation

If a detail affects the decision, it should appear near the proposed action. Placing an important unanswered question only in an attachment makes it easier to miss. The brief should explain whether that uncertainty prevents approval or permits a narrower next step.

An approver may reasonably authorise clarification without authorising expenditure. Equally, a budget allocation does not independently establish technical suitability. The record should state what the actual decision covers.

Make the commercial basis understandable

The financial section should identify the source and date of any figures used. A preliminary estimate should remain labelled as an estimate. If the organisation has requested a quotation but has not received one, the brief should avoid presenting a remembered website amount as an agreed total.

Relevant conditions should accompany the cost. These might include the proposed quantity or the period for which a quotation applies, where confirmed. Unverified details should not be added merely to make a comparison table look complete.

Explain who owns each remaining task

An approval brief becomes more practical when each unresolved point has a responsible person. The project team may need to assess descriptive information, purchasing may need to clarify terms and the budget holder may need to approve expenditure. These roles should be recorded without inventing a complicated process the organisation does not use.

The record should distinguish an external supplier answer from an internal judgement based on that answer. This makes later review easier and avoids attributing a decision to a party that only supplied information.

Preserve the approval actually given

After a decision, the brief should retain the version reviewed and the conditions attached. A later change in candidate, quantity or terms may require a further check. The original approval should not silently expand to cover a materially different proposal.

A concise, honest brief helps an approver make the right decision at the right stage. It can support a documented research purchase or a targeted request for more information. Its purpose is administrative and commercial clarity; it offers no assurance of medical safety, therapeutic benefit or suitability for personal administration.

EvoraCare product information

For current product specifications and availability, see the MOTS-C product page.